Mette S. van Ramshorst

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

Mette S. van Ramshorst, Anna van der Voort, Erik van Werkhoven et al. · The Lancet Oncology · 2018 · 413 citations · Full text

Breast Oncology, Oncology, Dual Her2 Blockade +7

Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual<i>ERBB2</i>Blockade in Patients With<i>ERBB2</i>-Positive Breast Cancer

Anna van der Voort, Mette S. van Ramshorst, Erik van Werkhoven et al. · JAMA Oncology · 2021 · 130 citations · Full text

Adjuvant chemotherapy in small node-negative triple-negative breast cancer

Tessa G. Steenbruggen, Erik van Werkhoven, Mette S. van Ramshorst et al. · European Journal of Cancer · 2020 · 117 citations · Full text

Breast Oncology, Medicine, Adjuvant Chemotherapy +4

MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy

Mette S. van Ramshorst, Claudette E. Loo, Emilie J. Groen et al. · Breast Cancer Research and Treatment · 2017 · 43 citations

Breast Oncology, Radiology, Pathologic Complete Response +8

Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study

Mette S. van Ramshorst, Erik van Werkhoven, Aafke H. Honkoop et al. · The Breast · 2016 · 38 citations · Full text